George J. Broze, Jr., M.D.

Internal Medicine
Cell Biology and Physiology

Biochemistry, Biophysics, and Structural Biology Program

  • 314-362-8811

  • 314-362-8863

  • 314-362-8826

  • 8125

  • 8804 Clinical Sciences Research Building


  • blood coagulation, atherosclerosis, biochemistry, kinetics, vascular biology

  • Regulation of coagulation

Research Abstract:

The goal of our research is an understanding of the initiation and control of hemostasis and the interrelationship between coagulation and inflammation. Rather than hemorrhagic phenomena, the investigative thrust concerns pathologic thrombosis and atherosclerosis.

Our investigations have recently centered on a novel endogenous coagulation inhibitor that circulates bound to plasma lipoproteins that we have isolated, cloned, expressed and characterized, called Tissue Factor Pathway Inhibitor (TFPI). TFPI is a multivalent Kunitz-type proteinase inhibitor that directly inactivates coagulation factor Xa and produces feedback inhibition of the factor VIIa/tissue factor catalytic complex, which is responsible for the initiation of coagulation. Additional work involves the characterization of a previously unrecognized regulator of coagulation we have termed the protein Z-dependent protease inhibitor. The aim of current studies is to define through both in vitro and in vivo experiments the role of coagulation in the inflammatory response and vascular diseases.

Work in the laboratory involves protein purification and characterization, kinetics of proteinase/inhibitor interactions, production of monoclonal and polyclonal antibodies for the development of immunoassays and histochemical studies, expression and characterization of native and mutant recombinant proteins for structure/function studies, and the assessment of particular interventions in animal models using transgenic and gene-deletion techniques.

Selected Publications:

Girard TJ, Lasky NM, Tuley EA, Broze GJ Jr. Protein Z, protein Z-dependent protease inhibitor (serpin A10), and the acute-phase response. J. Thromb. Haemost. 2013;11:375-378.

Butschkau A, Nagel P, Grambow E, Zechner D, Broze GJ Jr, Vollmar B. Contribution of protein Z and protein Z-dependent protease inhibitor in the general Shwartzman reaction. Crit. Care Med. 2013;e447-456.

Broze GJ Jr, Girard TJ. Factor V, tissue factor pathway inhibitor and the east Texas bleeding disorder. J. Clin. Invest. 2013;123:3710-3712.

Feng D, Stafford KA, Broze GJ, Stafford DW. Evidence of clinically significant extravascular stores of factor IX. J. Thromb. Haemost. 2013;11:2176-2178.

Broze GJ Jr. An acquired, calcium-dependent, factor X inhibitor. Blood Cells Mol. Diseases 2014;52:116-120.

van den Boogaard FE, Van`t Veer C, Roelofs JJ, Meijers JC, Schultz MJ, Broze GJ Jr, van der Poll T. Endogenous tissue factor pathway inhibitor has a limited effect on host defense in murine pneumococcal pneumonia. Thromb. Haemost 2015; April 2; 113. [Epub ahead of print]

Last Updated: 8/20/2015 11:20:59 AM

Back To Top

Follow us: